Amgen: pipeline and clinical trials
Amgen is developing olpasiran, a small interfering RNA that lowers lipoprotein(a), in two large cardiovascular outcomes trials. Amgen sponsors about 104 active clinical trials, with obesity and cardiovascular disease prominent.
Key points
- Amgen sponsors 104 active trials on ClinicalTrials.gov, 50 of them in Phase 3.
- Olpasiran's OCEAN(a)-Outcomes trial (7,297 participants) has an estimated primary completion in March 2028, likely the next major Lp(a) outcomes readout.
- A second olpasiran outcomes trial, OCEAN(a)-PreEvent (estimated 11,000 participants), is testing primary prevention.
- Amgen's largest active Phase 3 trial is MARITIME-CV (12,800 participants), a cardiovascular outcomes study of its obesity drug maridebart cafraglutide.
- Pelacarsen's 2026 Lp(a)HORIZON failure raises the stakes for Amgen's Lp(a) program.
Tracked drug profiles
Drugs from this company that Spectral Genomics profiles in depth, with registry data and sourced analysis.
Active clinical trials
ClinicalTrials.gov lists 104 active trials with Amgen as lead sponsor (recruiting, not yet recruiting, active, or enrolling by invitation), retrieved Nov 19, 2026. Counts include only trials whose lead sponsor is registered as "Amgen".
By phase
| Phase 1 | 27 |
| Phase 1/2 | 4 |
| Phase 2 | 13 |
| Phase 3 | 50 |
| Phase 4 | 7 |
| Not applicable | 3 |
Most common conditions
- Obesity (11)
- Overweight (8)
- Extensive Stage Small Cell Lung Cancer (4)
- Small Cell Lung Cancer (4)
- Prostate Cancer (3)
- Cardiovascular Disease (3)
- Neuromyelitis Optica Spectrum Disorder (3)
- Thyroid Eye Disease (3)
Conditions as registered by the sponsor; one trial can list several.
Largest active Phase 3 trials
| Trial | Enrollment | Primary completion |
|---|---|---|
| MARITIME-CV · NCT07037433 Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | 12,800 | Jun 30, 2028 |
| NCT07136012 OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction to Prevent First Major Cardiovascular Events | 11,000 | Oct 20, 2031 |
| NCT05581303 Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial | 7,297 | Mar 31, 2028 |
| MARITIME-HF · NCT07037459 Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | 5,056 | Jun 30, 2028 |
| MARITIME-1 · NCT06858839 Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 3,853 | Jan 21, 2027 |
| NCT07684235 Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) | 3,200 | Dec 26, 2027 |
| MARITIME-T2D-3 · NCT07866066 Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes | 1,300 | Sep 6, 2028 |
| MARITIME-2 · NCT06858878 Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 1,105 | Jan 21, 2027 |
| NCT07684144 Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) | 950 | Dec 26, 2027 |
| NCT06747949 A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) | 844 | Dec 11, 2029 |
Two big cardiovascular bets
According to the registry, Amgen's largest active late-stage programs are in cardiometabolic disease:
- Olpasiran for elevated lipoprotein(a), in OCEAN(a)-Outcomes and OCEAN(a)-PreEvent.
- Maridebart cafraglutide, an obesity drug, in cardiovascular (MARITIME-CV) and heart failure (MARITIME-HF) trials. Spectral Genomics does not yet profile this drug.
Amgen also markets evolocumab (Repatha), an injectable PCSK9 antibody. That gives it established experience in large cardiovascular outcomes trials.
What to watch
- OCEAN(a)-Outcomes, estimated primary completion March 2028 (registry). After Lp(a)HORIZON, this result will be read as a test of the Lp(a) hypothesis, not only of olpasiran.
- Any amendments to the olpasiran trials in the registry.
Recent milestones
- Nov 6, 2022OCEAN(a)-DOSE Phase 2 results for olpasiran published. Peer-reviewed
- Dec 14, 2022OCEAN(a)-Outcomes begins. Registry
- Aug 22, 2025OCEAN(a)-PreEvent begins. Registry
- Sep 4, 2026Read-across: pelacarsen's Lp(a)HORIZON outcomes trial misses its primary endpoint. Company-reported
Sources
- SEC EDGAR: Amgen Inc. filings (CIK 318154).Regulator
- O'Donoghue ML, et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. New England Journal of Medicine. 2022;387(20):1855–1864.Peer-reviewed
- ClinicalTrials.gov. OCEAN(a)-Outcomes (NCT05581303).Registry
- ClinicalTrials.gov. MARITIME-CV (NCT07037433).Registry
- ClinicalTrials.gov: active trials with this lead sponsorRegistry
This page is for education and research. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Company-reported information is labeled. See our disclaimer.